Anlotinib as third- or further-line therapy for short-term relapsed small-cell lung cancer: subgroup analysis of a randomized phase 2 study (ALTER1202)
Article in Frontiers of Medicine (July 2022)
The most recent citing publications are shown below. View all 14 publications that cite this research output on Dimensions.
Article in Frontiers of Medicine (July 2022)
Article in Dalton Transactions (November 2021)
Article in Canadian Respiratory Journal (November 2019)